PP63 Predictive markers in patients with upper gastrointestinal (GI) cancers treated with erlotinib and bevacizumab in a multicenter phase II trial

Autor:	Peter Carmeliet, Helle Pappot, Kristoffer Staal Rohrberg, Rene K Olesen, B. Guldhammer Skov, Per Pfeiffer, Ian Buysschaert, Morten Ladekarl, Ulrik Lassen, Ib Jarle Christensen
Rok vydání:	2009
Předmět:	Oncology Cancer Research medicine.medical_specialty Bevacizumab business.industry Internal medicine medicine Upper gastrointestinal In patient Erlotinib business medicine.drug
Zdroj:	European Journal of Cancer Supplements. 7:28
ISSN:	1359-6349
DOI:	10.1016/s1359-6349(09)72203-7
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::863b849c5ef502a1d23e77995037d2cb https://doi.org/10.1016/s1359-6349(09)72203-7 Zobrazit plný text záznamu Full Text from ScienceDirect